- A Solution to Accelerate Biopharmaceutical R&D -

Rigaku Corporation, a Rigaku Holdings Group company and global partner for X-ray analysis from Lab to Fab (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; "Rigaku"), has developed a technology called Electron Density Topography (“EDT”), patents pending. The new technology clarifies the structure and dynamic characteristics of biological macromolecules, including antibodies, protein complexes, and virus particles, in solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903386305/en/

EDT device (Photo: Business Wire)

EDT enables direct observation of biological macromolecules in solution, reducing artifacts resulting from measurement conditions. EDT is anticipated to improve the R&D processes for innovative biopharmaceuticals, including monoclonal antibody-based therapies and advanced drug delivery systems.

EDT provides information about the overall shape, molecular characteristics and internal structure of biological macromolecules from the distribution of electrons that determines a molecule's chemical properties. EDT has also enabled direct observation of the electron density of biological macromolecules without prior information about the samples.

In drug discovery, there is a clear need to determine at the early stages of development whether a drug has the expected structure and desired characteristics to optimize resources. EDT is a technology that meets this requirement and is expected to be used in basic research and development for biopharmaceuticals such as antibody drugs.

The first instrument with EDT capabilities will be deployed at Rigaku's Life Science Laboratory, a facility in Cambridge, Massachusetts, in Q4 2024.

Rigaku is committed to expanding its operations in the life sciences field, strengthening its presence to drive further innovation in collaboration with customers.

About The Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903386305/en/

Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
+81 90 6331 9843
prad@rigaku.co.jp

Logo

Images

Tags

More Like This

Rigaku BioScience Lab Opens in USA

Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure

Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology

Rigaku Joins Two Partners in Establishing RIGAKU/JEOL-iCeMS Innovation Core and Concluding a Cooperation Agreement

Rigaku Launches XTRAIA XD-3300 Mass Production for Semiconductor Market

Rigaku Develops Technology for 3D Visualization of the Atomic-scale Structure of Amorphous Carbon

Rigaku Wins Diana Nyyssonen Memorial Best Paper Award with Method for Inspecting and Measuring Defects in 3D Flash Memory